{Reference Type}: Journal Article
{Title}: Glutamine metabolism, a double agent combating or fuelling hepatocellular carcinoma.
{Author}: Ziki RA;Colnot S;
{Journal}: JHEP Rep
{Volume}: 6
{Issue}: 5
{Year}: 2024 May
{Factor}: 9.917
{DOI}: 10.1016/j.jhepr.2024.101077
{Abstract}: The reprogramming of glutamine metabolism is a key event in cancer more generally and in hepatocellular carcinoma (HCC) in particular. Glutamine consumption supplies tumours with ATP and metabolites through anaplerosis of the tricarboxylic acid cycle, while glutamine production can be enhanced by the overexpression of glutamine synthetase. In HCC, increased glutamine production is driven by activating mutations in the CTNNB1 gene encoding β-catenin. Increased glutamine synthesis or utilisation impacts tumour epigenetics, oxidative stress, autophagy, immunity and associated pathways, such as the mTOR (mammalian target of rapamycin) pathway. In this review, we will discuss studies which emphasise the pro-tumoral or tumour-suppressive effect of glutamine overproduction. It is clear that more comprehensive studies are needed as a foundation from which to develop suitable therapies targeting glutamine metabolic pathways, depending on the predicted pro- or anti-tumour role of dysregulated glutamine metabolism in distinct genetic contexts.